| Hapvida NotreDame Intermédica - One of the largest health plan operators in Brazil. |
Result of the merger between Hapvida and NotreDame Intermédica. Operates an extensive network with a focus on verticalization (owning hospitals, clinics, and diagnostic centers). Aims to control costs and improve care coordination. |
Significant M&A activity (merger). Strong presence in the health plan segment. Focus on integrated care through proprietary facilities. |
Over 8.8 million beneficiaries as of March 2024 (NotreDame Intermédica: 4.50 million, Hapvida: 4.31 million). |
The combined entity is expected to have significant revenue, but specific consolidated revenue for 2024 was not found in the provided sources. The total revenue for the health plan sector was approximately R$ 350 billion in 2024. |
| Grupo NC (includes EMS) - A major Brazilian pharmaceutical conglomerate. |
Includes EMS, one of the top pharmaceutical companies in Brazil by units sold. Involved in the research, development, manufacturing, and commercialization of a broad portfolio of medicines. |
Leads in sales value to pharmacies in Brazil. |
Not specified in the provided sources. |
Total revenue of R$ 26.4 billion with sales to pharmacies in 2024. |
| Eurofarma - A prominent Brazilian pharmaceutical company. |
Known for its significant growth in the market. Involved in the production and sale of pharmaceuticals in various therapeutic areas. Has a presence in several Latin American countries. |
Showed strong growth in 2024. |
Not specified in the provided sources. |
Presented one of the highest increases in revenue in 2024 among major pharmaceutical companies in Brazil, reaching the second position in sales to pharmacies. Specific revenue figure for 2024 from sales to pharmacies was not explicitly stated in the provided sources, but it is positioned second after Grupo NC's R$ 26.4 billion. |
| Bradesco Saúde - A major health insurance company linked to a large financial group. |
Primarily operates through a wide accredited network of hospitals, clinics, and professionals across Brazil. Offers a variety of health insurance plans with different levels of coverage and options for reimbursement. Caters to both corporate and individual clients. |
Part of the larger Bradesco financial group. Known for wide national coverage. |
3.81 million beneficiaries as of March 2024. |
Specific revenue for Bradesco Saúde was not explicitly stated, but the health plan sector's total revenue was approximately R$ 350 billion in 2024. |
| AMIL ASSISTENCIA MEDICA (Amil) - A significant health plan operator. |
Has a strong presence, particularly in major urban centers. Offers a range of plans with varying coverage and coparticipation options. Operates through accredited and some proprietary facilities. |
Mentioned as one of the "seven sisters of health" indicating its significant influence. |
3.16 million beneficiaries as of March 2024. |
Specific revenue for Amil was not explicitly stated, but the health plan sector's total revenue was approximately R$ 350 billion in 2024. |
| Rede D'Or - One of the largest hospital networks in Brazil. |
A major player in the healthcare services segment, primarily operating hospitals. |
Mentioned as one of the "seven sisters of health" indicating its significant influence. Listed among the largest companies in Brazil by market value in August 2024. |
Not specified in the provided sources. Brazil had approximately 3,900 private hospitals in late 2024. [See Value Chain Summary Table] |
Market value of R$ 74 billion in August 2024. Specific revenue for 2024 was not explicitly stated in the provided sources. |
| DASA - A leading company in diagnostic medicine in Brazil and Latin America. |
Operates a wide network of laboratories and diagnostic imaging centers under various brands (e.g., Delboni Auriemo, Lavoisier). Offers a comprehensive range of diagnostic tests. |
Mentioned as one of the "seven sisters of health" indicating its significant influence. |
The Brazilian diagnostic medicine market performed 2.2 billion exams in 2022. [See Value Chain Summary Table] |
The Brazilian diagnostic medicine market had a gross revenue of R$ 40 billion in 2022 and R$ 48.9 billion in 2023. [See Value Chain Summary Table, 23] Specific revenue for Dasa in 2024 was not explicitly stated. |
| LABORATORIO FLEURY (Grupo Fleury) - A major player in the diagnostic medicine market. |
Known for its quality and breadth of services, including clinical analyses and diagnostic imaging. Operates through Patient Service Units (B2C), Lab to Lab (B2B), New Links, and Health Platforms. |
Invested in technology and artificial intelligence in 2023. Completed the combination of business with Hermes Pardini in April 2023. |
Processed 186 million exams in 2024 in the B2B segment. The Brazilian diagnostic medicine market performed 2.2 billion exams in 2022. [See Value Chain Summary Table] |
Revenue of R$ 7.5 billion in the last twelve months ending June 2024. Gross revenue of R$ 1.958 billion in the B2B segment in 2024. The Brazilian diagnostic medicine market had a gross revenue of R$ 40 billion in 2022 and R$ 48.9 billion in 2023. [See Value Chain Summary Table, 23] |
| Sabin Medicina Diagnóstica - A significant laboratory group. |
Has a presence in multiple Brazilian regions. Offers clinical analyses, imaging, and vaccination services. |
Has been active in acquisitions since 2019. Migrated units to a single operating system in 2023. |
Not specified in the provided sources. The Brazilian diagnostic medicine market performed 2.2 billion exams in 2022. [See Value Chain Summary Table] |
Not specified in the provided sources. The Brazilian diagnostic medicine market had a gross revenue of R$ 40 billion in 2022 and R$ 48.9 billion in 2023. [See Value Chain Summary Table, 23] |
| ONCOCLINICAS DO BRASIL SERVICOS (Oncoclínicas) - One of the largest oncology groups in Latin America. |
Provides services in oncology, hematology, and radiotherapy. Operates through numerous units across Brazil. |
Its area of operation in Brazil covers 12 states through 70 units. |
Operates in 12 states through 70 units. |
Specific revenue for 2024 was not explicitly stated in the provided sources. |